Skip to main content Skip to footer
Nighthawk Biosciences, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Biothreat Advisory Board
  • Ecosystem
    • Overview
    • Subsidiaries
  • Products
    • Anthim
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Corporate Presentation
  • Careers
  • Contact

Press Releases

Investors & News

Investors & News

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Corporate Presentation
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 12, 2019 7:00am EDT

Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110

Aug 07, 2019 11:15am EDT

Heat Biologics CEO and Lead Director to Participate in German Investor Forums

Jul 09, 2019 8:00am EDT

Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

Jun 03, 2019 6:55am EDT

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

May 20, 2019 8:30am EDT

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

May 15, 2019 7:30am EDT

Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

May 06, 2019 7:00am EDT

Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

Apr 18, 2019 5:30pm EDT

Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

Apr 02, 2019 8:00am EDT

Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019

Mar 28, 2019 7:30am EDT

Heat Biologics Reports 2018 Results and Provides Corporate Update

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Page 29
  • Next Pagearrow_forward
rss_feed News RSS
NightHawk Biosciences

OUR ECOSYSTEM

SkunkWorx Bio
Elusys Therapeutics Inc.
Scorpius Biological Services
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Nighthawk Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap
  • Visit us on LinkedIn
  • Visit us on Twitter
  • Visit us on YouTube
  • Visit us on Facebook

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.